Table 1: Demographic and Clinical characteristics of adults receiving repeat kidney transplants in the United States from 2003 through 2013.

VariablesAntithymocyte globulinAlemtuzumab
Basiliximab
p Value

Donor type:<.001
 Expanded criteria deceased475 (5.21)116 (6.88)106 (4.96)
 Standard criteria deceased6008 (65.88)996 (59.04)1103 (51.61)
 Living2637 (28.91)575 (34.08)928 (43.43)
Donor race:<.001
 Black1145 (12.55)206 (12.21)191 (8.94)
 Others7975 (87.45)1481 (87.79)1946 (91.06)
Recipient age, years:
 Mean (SD)44.36 (12.59)44.69 (13.07)46.15 (13.43)<.001
 Range18–7818–7918–88
Recipient race:<.001
 Black2077 (22.77)389 (23.06)314 (14.69)
 Others7043 (77.23)1298 (76.94)1823 (85.31)
Primary kidney disease:
 Glomerulonephritis3417 (37.47)632 (37.46)776 (36.31)0.60
Pretransplant dialysis:<.001
 1 day–1 year1392 (15.26)291 (17.25)462 (21.62)
 >1 year6515 (71.44)1154 (68.41)1217 (56.95)
 No dialysis1213 (13.30)242 (14.34)458 (21.43)
Pretransplant PRA:<.001
 PRA 0–20%2408 (26.40)446 (26.44)981 (45.91)
 PRA > 20%6712 (73.60)1241 (73.56)1156 (54.09)
HLA mismatch<.001
 0–34215 (46.31)801 (47.57)1116 (52.30)
 More than 34886 (53.69)883 (52.43)1018 (47.70)
Transplant year:<.001
 2003–20084344 (47.63)656 (38.89)1299 (60.79)
 2009–20134776 (52.37)1031 (61.11)838 (39.21)
Steroids included in maintenance Immunosuppression regimen:<.001
 No1468 (16.10)817 (48.43)232 (10.86)
 Yes7652 (83.90)870 (51.57)1905 (89.14)